Page 1

amneal Exhibit 99.1 AMNEAL REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS -Q3 2021 Net Revenue of $ 529 million ; GAAP Net Loss of $ ( 4 ) million ; Diluted Loss per Share of $ ( 0.03 ) - - Adjusted EBITDA of $ 135 million ; Adjusted Diluted EPS ( 1 ) of $ 0.21 - - Updating 2021 Full Year Financial Outlook , Including Raising Adjusted EBITDA and Adjusted EPS Guidance - - Announces Acquisition of Puniska Healthcare to Significantly Expand Injectable Business - BRIDGEWATER , NJ , November 3 , 2021 - Amneal Pharmaceuticals , Inc. ( NYSE : AMRX ) ( " Amneal " or the " Company " ) announced its results today for the third quarter ended September 30 , 2021 . " Our solid third quarter results further validate our strategy for growth and value creation , focused on operational excellence and a robust innovation engine to strengthen and diversify Amneal , " said Chirag and Chintu Patel , Co - Chief Executive Officers . " We are pleased to be raising our adjusted EBITDA guidance for full year 2021 , underscoring our continued strong business performance . We are also excited to announce the acquisition of Puniska , and we welcome the Puniska team to the Amneal family . This acquisition is a pivotal step that meaningfully enhances our injectables capabilities for the U.S. market and enables international expansion as we look to become a leading player in the global injectables market , ” said Chirag and Chintu Patel , Co - Chief Executive Officers . Net revenue in the third quarter of 2021 was $ 529 million , an increase of 2 % compared to $ 519 million in the third quarter of 2020. The increase was driven by Generic product launches and growth in our promoted Specialty products RytaryⓇ and Unithroid® , partially offset by price erosion in our base business and slow demand at the start of the flu season . Net loss attributable to Amneal Pharmaceuticals , Inc. was $ 4 million in the third quarter of 2021 compared to a net loss of $ 9 million in the third quarter of 2020. The decrease in net loss was primarily attributable to growth in net revenue and gross profit , which was driven by strong gross margin improvement in our Generics segment and a reduction in impairment charges . Adjusted EBITDA ( 1 ) in the third quarter of 2021 was $ 135 million , an increase of 19 % compared to the third quarter of 2020 , reflective of an increase in gross profit . Adjusted diluted EPS ( ¹ ) in the third quarter of 2021 was $ 0.21 , an increase of 31 % from $ 0.16 in the third quarter of 2020 , reflective mostly of growth in adjusted EBITDA ( ¹ ) . ( 1 ) See " Non - GAAP Financial Measures " below . Updating Full Year 2021 Financial Outlook Amneal is updating its previously provided guidance . Net revenue Adjusted EBITDA ( 1 ) Adjusted diluted EPS ( 2 ) Operating cash flow Capital expenditures Weighted average diluted shares outstanding ( 3 ) ( ¹ ) Includes 100 % of EBITDA from the AvKARE acquisition . Existing Full Year 2021 Guidance $ 2.1 billion $ 2.2 billion $ 500 million - $ 540 million $ 0.70 - $ 0.85 $ 220 million - $ 250 million $ 60 million - $ 70 million Approximately 303 million ( 2 ) Accounts for 35 % non - controlling interest in AvKARE and reflects the current federal tax rate of 21 % . Revised Full Year 2021 Financial Guidance ~ $ 2.1 billion ( 3 ) Assumes the weighted average diluted shares outstanding of class A and class B common stock under the if - converted method . $ 530 million - $ 550 million $ 0.78 $ 0.88 $ 220 million - $ 250 million $ 50 million $ 60 million Approximately 304 million 1